Professor Dickinson is the Lead of the Aggressive Lymphoma stream and cares for patients with all forms of lymphoma, myeloma, MDS and AML. He is the convenor of the lymphoma MDM, Deputy Clinical Lead of the CAR-T Centre of Excellence, and Chair of the Lymphoma Working Party of the Australasian Leukaemia and Lymphoma Group and the Chair of the Clinical Research Committee at Peter Mac. He is interested in in drug development and as PI, treated the first patient globally in multiple first-in-human clinical trials, and taken several drugs to registration. Professor Dickinson treated the first patients globally in the trials of glofitamab (bispecific antibody for lymphoma), epigenetic agents (BET inhibitors), NKX019 (CAR-NK cells), YTB323 (rapcabtagene autoleucel), ELARA (CAR-T registration trial for follicular lymphoma). His team were the first to use YESCARTA and KYMRIAH in trials and commercially in Australia, the highest ex-US recruiters to pivotal trials of CAR-T in DLBCL and follicular lymphoma. Professor Dickinson was a lead investigator in the registration trial of the first-in-class agent glofitamab. He has over 100 publications including in New England Journal of Medicine, Nature Medicine, the Journal of Clinical Oncology and Blood. Professor Dickinson supports research fellows and PhD students through their professional development. Although he enjoys academic medicine, his greatest professional satisfaction comes from making individual patients feel better. He believes in research-led clinical care, and placing a patient’s individual circumstances to the fore when developing a treatment plan that is not only evidence-based, but which is also right for them.